Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoChange DetectedThe notice about a lapse in government funding and related operating-status updates has been removed from the page.SummaryDifference0.3%

- Check31 days agoChange DetectedThe update appears to show only minor layout adjustments with no changes to the core study content, such as design, endpoints, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check60 days agoChange DetectedCore content updated with new government-status notice and version 3.2.0; a specific resource entry (Small cell lung carcinoma) was deleted (v3.1.0).SummaryDifference4%

- Check67 days agoChange Detected- Updated the page version from v3.0.2 to v3.1.0. Minor overall impact, mainly reflects a version increment.SummaryDifference0.1%

- Check81 days agoChange DetectedUpdated the page from v3.0.1 to v3.0.2; removed the Back to Top link as a minor UI cleanup. No changes to pricing, stock availability, or time slots.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.